Wedge Capital Management L L P NC Grows Position in Pfizer Inc. $PFE

Key Points

• Wedge Capital Management L L P NC increased its stake in Pfizer by 8.0% in Q4 to 1,141,163 shares, valued at about $28.4 million.
• Pfizer beat Q4 expectations with $0.66 EPS (vs. $0.57 est.) and $17.56B revenue (vs. $16.93B est.), though revenue was down 1.2% year‑over‑year and analysts project roughly 2.95 EPS for the year.
• Market sentiment is mixed: recent late‑stage clinical wins and analyst upgrades support upside, but political pricing risks and dividend sustainability concerns weigh on valuation; consensus rating is a Hold with an average target of $28.19.

Wedge Capital Management L L P NC boosted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 8.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,141,163 shares of the biopharmaceutical company's stock after buying an additional 84,924 shares during the quarter. Wedge Capital Management L L P NC's holdings in Pfizer were worth $28,415,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Fiduciary Alliance LLC lifted its holdings in Pfizer by 46.4% in the third quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company's stock valued at $3,701,000 after acquiring an additional 46,043 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in shares of Pfizer during the 3rd quarter valued at about $3,019,000. Vista Investment Partners LLC increased its position in shares of Pfizer by 236.1% during the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company's stock valued at $1,774,000 after purchasing an additional 48,900 shares during the last quarter. Money Concepts Capital Corp lifted its stake in shares of Pfizer by 29.9% in the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company's stock worth $6,325,000 after purchasing an additional 57,188 shares during the period. Finally, Kepler Cheuvreux Suisse SA purchased a new position in shares of Pfizer in the third quarter worth approximately $16,613,000. Institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

NYSE PFE opened at $27.03 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94. The stock has a market cap of $153.70 billion, a price-to-earnings ratio of 19.88 and a beta of 0.47. The company's 50 day moving average is $26.84 and its two-hundred day moving average is $25.68.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts' consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company's revenue was down 1.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.63 earnings per share. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Late‑stage clinical wins broaden Pfizer’s pipeline beyond COVID — a partnered 6‑valent Lyme vaccine showed ~75% Phase 3 efficacy and several oncology/immunology programs met key endpoints, supporting a re‑rating of growth prospects. Should Pfizer’s (PFE) New Lyme Vaccine and Oncology Wins Reshape Its Post‑COVID Pipeline Story?
• Positive Sentiment: Guggenheim raised its price target and reiterated a Buy, citing favorable risk/reward ahead of Phase 3 MEVPRO‑1 data — that analyst support can underpin short‑term investor interest. Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data
• Positive Sentiment: Multiple bullish notes and “strong buy” theses are circulating after recent trial/portfolio progress, which can attract income and value investors looking for upside plus yield. Why Pfizer Remains A Strong Buy In 2026
• Neutral Sentiment: Jim Cramer mentioned PFE but said he needs more clarity on product flow — a reminder that mainstream TV coverage can move short‑term flows but hasn’t changed fundamentals. Jim Cramer on Pfizer: “I Just Need to Know Their Product Flow Better”
• Neutral Sentiment: Citi and other outlets continue to rate PFE around Hold/Neutral — signaling mixed analyst conviction despite select upgrades. Citi Remains a Hold on Pfizer (PFE)
• Negative Sentiment: A bearish view argues Wall Street overestimates PFE’s target price, pointing to political threats (e.g., “TrumpRx”, most‑favored‑nation pricing) that could compress margins and support a multi‑year earnings downside. That policy risk is pressuring valuation. Pfizer: Why Wall Street Habitually Overestimates Target Price
• Negative Sentiment: Income‑focused coverage flags payout safety concerns: Pfizer’s high yield draws attention but raises questions about sustainability if earnings weaken, which can amplify downside for dividend investors. Income Investors Face a Hard Truth About Pfizer’s Payout Safety

Analyst Upgrades and Downgrades

PFE has been the subject of several recent research reports. UBS Group initiated coverage on shares of Pfizer in a research report on Tuesday, January 6th. They set a "neutral" rating and a $25.00 target price for the company. Cantor Fitzgerald reiterated a "neutral" rating and issued a $27.00 price target on shares of Pfizer in a research report on Wednesday, February 4th. Daiwa Securities Group cut shares of Pfizer from an "outperform" rating to a "neutral" rating and set a $27.00 price target on the stock. in a research note on Thursday, February 12th. Weiss Ratings restated a "hold (c-)" rating on shares of Pfizer in a research note on Thursday, January 22nd. Finally, Bank of America decreased their target price on Pfizer from $29.00 to $28.00 and set a "neutral" rating on the stock in a report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, Pfizer presently has an average rating of "Hold" and an average price target of $28.19.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.